Cryoport reports second quarter 2023 financial results

Second quarter revenue of $57 million, in line with previously announced preliminary results clinical trials supported by cryoport increased to a record 668 global clinical trials by quarter end; a net increase of 42 new trials added year-over-year strong balance sheet with over $500 million in cash and short-term investments nashville, tenn. , aug. 9, 2023 /prnewswire/ -- cryoport, inc. (nasdaq: cyrx) ("cryoport" or the "company"), a leading global provider of innovative products and services to the fast-growing cell & gene therapy industry enabling the future of medicine for a new era of life sciences, today announced financial results for the second quarter (q2) and first half (h1) of 2023.
CYRX Ratings Summary
CYRX Quant Ranking